Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
219 Leser
Artikel bewerten:
(1)

Hardman & Co Research: International Biotechnology Trust (IBT) - Access to fast-growing biotechnology companies

DJ Hardman & Co Research: International Biotechnology Trust (IBT) - Access to fast-growing biotechnology companies

Hardman & Co Research Hardman & Co Research: International Biotechnology Trust (IBT) - Access to fast-growing biotechnology companies 03-Dec-2021 / 11:15 GMT/BST

-----------------------------------------------------------------------------------------------------------------------

Hardman & Co Research: Access to fast-growing biotechnology companies

IBT was established in 1994 to provide institutional and retail investors with the opportunity to participate in global biotechnology and life science companies, from venture-stage (via a venture capital fund run by SV Health Investors) through to global, multinational biotechnology companies. The main aim of the trust is to generate capital growth, while minimising risk, through a diversified portfolio and with an experienced investment management team. Over the last five years, IBT's NAV per share has increased 64%, while the share price has increased 79% over the same period - the superior returns generally reflected by a share price premium.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/access-to-fast-growing-biotechnology-companies/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us: 
Hardman & Co            Contact: 
1 Frederick's Place 
                  Martin Hall 
London                        mh@hardmanandco.com 
EC2R 8AE 
                  +44(0)20 3693 7075 
www.hardmanandco.com 
Follow us on Twitter @HardmanandCo 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

-----------------------------------------------------------------------------------------------------------------------

Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

End of Announcement - EQS News Service

1254127 03-Dec-2021

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1254127&application_name=news

(END) Dow Jones Newswires

December 03, 2021 06:15 ET (11:15 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2021 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.